Report cover image

Bleeding Disorder Testing Market

Publisher Fortune Business Insights Pvt. Ltd.
Published Oct 01, 2024
Length 130 Pages
SKU # FOB19260714

Description

Bleeding Disorder Testing Market



Growth Factors of Bleeding Disorder Testing Market

The bleeding disorder testing market size was valued at USD 88.5 million in 2022, and the market is now projected to grow from USD 94.9 million in 2023 to USD 161.9 million by 2030, exhibiting a CAGR of 7.9% during the forecast period of 2023-2030.

The market for hemophilia A and B treatments and other bleeding disorders was affected by the COVID-19 pandemic because patient visits and diagnostic procedures reduced. There arose a tendency among healthcare providers to concentrate mostly on COVID-19 testing to the neglect of other health threatening diseases. Also, the current-patient fear of infection decimated the number of tests performed for bleeding disorders.

The hike in frequency of diseases such as Hemophilia A, B, and idiopathic thrombocytopenic purpura has put pressure on the number of patients with bleeding disorders. The increase is felt both in developed and emerging parts due to various genetic factors leading to increased patient pools.

The growing incidence due to the genetic factors that include hemophilia A, B and ITP is expanding the patient base. This rise is for both developed as well as the emerging regions. Such several patients speak for the need to improve the diagnostic and therapeutic methods.

Comprehensive Analysis of Bleeding Disorder Testing Market

The bleeding disorder testing market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly provides a thorough market breakdown near to the industry considering the leading supply and demand forces. These segmentations are methodically segregated by product type analysis, by indication analysis, and by end-user analysis. By product type analysis include reagents & consumables and instruments. By indication analysis include hemophilia A, Von Willebrand disease, hemophilia B, idiopathic thrombocytopenic purpura, and others. By end-user analysis include hospitals & clinics, diagnostic centers, and others.

The Europe region lead the bleeding disorder testing market share by benefitting a market size of USD 35.5 million in 2023 due to increasing prevalence of bleeding disorders.

The top players in the markets have a central responsibility in the healthcare industry to be sure of industrial prospectus development and to establish the market norms. These players include, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, HORIBA Ltd, Sysmex Corporation, Abbott, Thermo Fisher Scientific Inc., Atlas Medical GmbH, HYPHEN BioMed, Precision Biologics these market players provide a level-playing competitive landscape.

In July 2022, HORIBA, Ltd. launched new products in its Yumizen H500 and H550 hematology product family, offering increased benefits, new features, and improved performance.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2030

Base Year 2022

Forecast Period 2023-2030

Historical Period 2019-2021

Unit Value (USD Million)

Growth Rate CAGR of 7.9% from 2023-2030

Segmentation By Product Type, Indication, End-user, and Region

By Product Type Reagents & Consumables

Instruments

By Indication Hemophilia A

Hemophilia B

Von Willebrand Disease

Idiopathic Thrombocytopenic Purpura

Others

By End-user Hospitals & Clinics

Diagnostic Centers

Others

By Geography North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)

Rest of the World

Table of Contents

130 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Prevalence of Bleeding Disorders, by Key Countries, 2022
4.2. New Product Launches, By Key Players
4.3. Technological Advancements in the Global Bleeding Disorders Testing Market
4.4. Impact of COVID-19 on the Market
5. Global Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2019-2030
5.1. Market Analysis, Insights and Forecast – By Product Type
5.1.1. Reagents & Consumables
5.1.2. Instruments
5.2. Market Analysis, Insights and Forecast – By Indication
5.2.1. Hemophilia A
5.2.2. Hemophilia B
5.2.3. Von Willebrand Disease
5.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
5.2.5. Others
5.3. Market Analysis, Insights and Forecast – By End-user
5.3.1. Hospitals & Clinics
5.3.2. Diagnostic Centers
5.3.3. Others
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Rest of the World
6. North America Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2019-2030
6.1. Market Analysis, Insights and Forecast – By Product Type
6.1.1. Reagents & Consumables
6.1.2. Instruments
6.2. Market Analysis, Insights and Forecast – By Indication
6.2.1. Hemophilia A
6.2.2. Hemophilia B
6.2.3. Von Willebrand Disease
6.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
6.2.5. Others
6.3. Market Analysis, Insights and Forecast – By End-user
6.3.1. Hospitals & Clinics
6.3.2. Diagnostic Centers
6.3.3. Others
6.4. Market Analysis, Insights and Forecast – By Country
6.4.1. U.S.
6.4.2. Canada
7. Europe Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2019-2030
7.1. Market Analysis, Insights and Forecast – By Product Type
7.1.1. Reagents & Consumables
7.1.2. Instruments
7.2. Market Analysis, Insights and Forecast – By Indication
7.2.1. Hemophilia A
7.2.2. Hemophilia B
7.2.3. Von Willebrand Disease
7.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
7.2.5. Others
7.3. Market Analysis, Insights and Forecast – By End-user
7.3.1. Hospitals & Clinics
7.3.2. Diagnostic Centers
7.3.3. Others
7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
7.4.1. U.K
7.4.2. Germany
7.4.3. France
7.4.4. Spain
7.4.5. Italy
7.4.6. Scandinavia
7.4.7. Rest of Europe
8. Asia Pacific Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2019-2030
8.1. Market Analysis, Insights and Forecast – By Product Type
8.1.1. Reagents & Consumables
8.1.2. Instruments
8.2. Market Analysis, Insights and Forecast – By Indication
8.2.1. Hemophilia A
8.2.2. Hemophilia B
8.2.3. Von Willebrand Disease
8.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
8.2.5. Others
8.3. Market Analysis, Insights and Forecast – By End-user
8.3.1. Hospitals & Clinics
8.3.2. Diagnostic Centers
8.3.3. Others
8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. Southeast Asia
8.4.6. Rest of Asia Pacific
9. Rest of the World Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2019-2030
9.1. Market Analysis, Insights and Forecast – By Product Type
9.1.1. Reagents & Consumables
9.1.2. Instruments
9.2. Market Analysis, Insights and Forecast – By Indication
9.2.1. Hemophilia A
9.2.2. Hemophilia B
9.2.3. Von Willebrand Disease
9.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
9.2.5. Others
9.3. Market Analysis, Insights and Forecast – By End-user
9.3.1. Hospitals & Clinics
9.3.2. Diagnostic Centers
9.3.3. Others
10. Competitive Analysis
10.1. Global Market Share Analysis (2022)
10.2. Company Profiles
10.2.1. Siemens Healthcare GmbH
10.2.1.1. Overview
10.2.1.2. Product
10.2.1.3. SWOT Analysis
10.2.1.4. Recent Developments
10.2.1.5. Strategies
10.2.1.6. financials (Based on Availability)
10.2.2. F. Hoffmann-La Roche Ltd.
10.2.2.1. Overview
10.2.2.2. Product
10.2.2.3. SWOT Analysis
10.2.2.4. Recent Developments
10.2.2.5. Strategies
10.2.2.6. financials (Based on Availability)
10.2.3. Thermo Fisher Scientific Inc.
10.2.3.1. Overview
10.2.3.2. Product
10.2.3.3. SWOT Analysis
10.2.3.4. Recent Developments
10.2.3.5. Strategies
10.2.3.6. financials (Based on Availability)
10.2.4. Abbott Laboratories
10.2.4.1. Overview
10.2.4.2. Product
10.2.4.3. SWOT Analysis
10.2.4.4. Recent Developments
10.2.4.5. Strategies
10.2.4.6. financials (Based on Availability)
10.2.5. Atlas Medical GmbH
10.2.5.1. Overview
10.2.5.2. Product
10.2.5.3. SWOT Analysis
10.2.5.4. Recent Developments
10.2.5.5. Strategies
10.2.5.6. financials (Based on Availability)
10.2.6. HORIBA, Ltd.
10.2.6.1. Overview
10.2.6.2. Product
10.2.6.3. SWOT Analysis
10.2.6.4. Recent Developments
10.2.6.5. Strategies
10.2.6.6. financials (Based on Availability)
10.2.7. Sysmex Corporation
10.2.7.1. Overview
10.2.7.2. Product
10.2.7.3. SWOT Analysis
10.2.7.4. Recent Developments
10.2.7.5. Strategies
10.2.7.6. financials (Based on Availability)
10.2.8. HYPHEN BioMed
10.2.8.1. Overview
10.2.8.2. Product
10.2.8.3. SWOT Analysis
10.2.8.4. Recent Developments
10.2.8.5. Strategies
10.2.8.6. financials (Based on Availability)
10.2.9. Precision BioLogic Incorporated
10.2.9.1. Overview
10.2.9.2. Product
10.2.9.3. SWOT Analysis
10.2.9.4. Recent Developments
10.2.9.5. Strategies
10.2.9.6. financials (Based on Availability)
10.2.10. Other Players

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us